Microba Life Sciences Announces Q4 FY26 Report Release and Investor Webinar on 16 July 2026

Microba Life Sciences Sets 16 July 2026 for Q4 FY26 Quarterly Report Publication

Microba Life Sciences Limited has officially confirmed the release of its Q4 FY26 Quarterly Activities Report and Appendix 4C on Thursday, 16 July 2026. The Appendix 4C, a mandatory quarterly cash flow statement under ASX Listing Rules for companies yet to achieve sustained profitability, is closely monitored by investors in life sciences and healthcare technology sectors. Alongside this, the company will issue a Quarterly Investor Presentation to provide comprehensive operational insights complementing the financial disclosures.

The simultaneous publication of the Quarterly Activities Report, Appendix 4C, and Investor Presentation aligns with Microba’s commitment to transparent, timely communication with shareholders. No financial previews or guidance regarding cash flows, revenue, or expenses have been disclosed ahead of the release. Investors will need to review the full documentation on 16 July 2026 to assess the company’s financial performance. The announcement did not include any anticipated financial outcomes for the quarter.

CEO Dr Luke Reid to Lead Microba’s Q4 FY26 Investor Webinar at 12:00pm AEST

The Quarterly Investor Webinar will be hosted by Microba’s CEO, Dr Luke Reid, at 12:00pm AEST (Brisbane/Sydney/Melbourne time) on Thursday, 16 July 2026. This live session is designed to provide investors and stakeholders with direct access to company leadership following the report release. Attendance requires prior registration via Microba’s interactive Investor Hub.

Dr Reid’s direct involvement in presenting the webinar highlights Microba’s proactive investor relations approach, ensuring shareholders hear firsthand insights rather than through delegated representatives. This engagement strategy allows investors to gain clarity on the quarter’s activities, progress against company milestones, and near-term priorities. Registration details are accessible through Microba’s Investor Hub platform.

Submitting Questions Ahead of the Microba Q4 FY26 Webinar

Microba encourages investors and interested parties to submit questions in advance using the 'Ask a question' feature on its Investor Hub platform. This tool enables shareholders to raise topics or seek clarifications on operational or financial matters before the live webinar. A direct link to register and submit questions is provided on the company’s Investor Hub.

This pre-submission option supports broader investor participation, especially for those unable to attend live or ask questions in real time. It ensures a wider range of shareholder interests are addressed during the presentation. The company has not specified how questions will be selected or prioritized during the webinar. Early registration is advised to secure participation ahead of the 12:00pm AEST start on 16 July 2026.

Microba Life Sciences’ Focus on Clinical-Grade Microbiome Testing

Microba Life Sciences Limited positions itself at the forefront of microbiome health and human care, focusing on clinical-grade microbiome tests that help individuals understand gut health’s impact on overall wellbeing. The company’s vision is driven by world-class science, insights, and collaboration tools, aiming to help people live healthier, happier lives. Operating under the slogan "Expect better," Microba promotes its services with the tagline "Better science. Better insights. Better health."

Headquartered in Brisbane, Queensland, at Level 10, 324 Queen Street, Microba holds ABN 82 617 096 652 and trades on the Australian Securities Exchange under ticker MAP. The microbiome diagnostics sector is an emerging field within life sciences, gaining momentum as research reveals the gut microbiome’s role in disease, immunity, and mental health. Microba’s position in this growing market makes its quarterly disclosures highly relevant for investors monitoring microbiome healthcare commercialisation in Australia.

Investor Hub Platform Enables Shareholders to Stay Updated

Microba’s interactive Investor Hub, accessible at ir.microba.com/welcome, serves as the central resource for shareholders and interested parties to obtain company updates, register for webinars, and receive notifications about quarterly reports and key announcements. New users can easily register by visiting the site, creating an account, and completing their profile to receive tailored alerts.

This Investor Hub reflects a broader trend among ASX-listed companies toward dynamic, interactive shareholder engagement beyond traditional announcement portals. For Microba, operating in a specialized technical field, this platform helps bridge communication between management and retail investors. The 16 July 2026 announcement will also be available on the Investor Hub via a dedicated link. Investors who have not yet registered are encouraged to do so for timely access to Q4 FY26 materials.

Importance of the Appendix 4C Cash Flow Report for Microba Investors

The Appendix 4C is a mandatory quarterly report for ASX-listed companies that have not reached sustained profitability or meet specific revenue thresholds. For Microba investors, this report provides critical insights into the company’s cash position, operating cash flow, and customer receipts. These metrics are key indicators of whether Microba has sufficient funds to continue operations and achieve upcoming milestones without needing additional capital.

Operating within the life sciences sector, which demands ongoing investment in research and commercialisation, the Appendix 4C holds substantial significance for assessing Microba’s financial health. The company has not disclosed any specific figures from the forthcoming Appendix 4C prior to the 16 July 2026 release. Investors and analysts will carefully review changes in cash receipts, operating expenses, and the quarter-end cash balance. No forecasted cash flow or revenue figures for Q4 FY26 were provided in the announcement.

Governance and Authorisation of Microba’s Q4 FY26 Update

The announcement confirming the Q4 FY26 reporting timeline and webinar details was authorised by both the Chair and CEO of Microba Life Sciences Limited. This dual approval aligns with standard ASX governance practices for releasing market-sensitive and investor-relevant information. Their involvement ensures the communication has undergone thorough review at the highest executive and board levels before public release.

For further information, the primary contact is Dr Luke Reid, CEO, reachable at [email protected]. Providing direct CEO contact details underscores Microba’s commitment to accessible investor communications, consistent with its interactive Investor Hub approach. Institutional investors and media seeking additional context before or after the 16 July 2026 webinar and report release are encouraged to use this official channel.

Key Focus Areas for Investors in Microba’s Q4 FY26 Report

Upon release of the Q4 FY26 Quarterly Activities Report and Appendix 4C on 16 July 2026, Microba investors will likely concentrate on several critical disclosures. The Appendix 4C’s cash flow data—including customer receipts, operating cash usage, and closing cash balance—will be pivotal in evaluating the company’s short-term financial viability. Updates on Microba’s core commercial activities, such as the adoption and rollout of its clinical-grade microbiome testing products, may also be highlighted.

As an early to mid-stage life sciences company, investors will pay close attention to any strategic commentary or guidance offered by Dr Luke Reid during the webinar regarding pipeline progress, milestones, and future priorities. No preview of such commentary was provided ahead of the webinar. Investors should remain mindful of the inherent risks tied to commercialising innovative diagnostic technologies, including clinical adoption rates, reimbursement challenges, and competitive pressures within the microbiome testing market. The announcement’s immediate impact on Microba’s share price was unclear, as it primarily addresses logistical details rather than material financial disclosures.